Abstract
The radiation and radiomimetic drugs used to treat human tumors damage DNA in both cancer cells and normal proliferating cells. Centrosome amplification after DNA damage is well established for transformed cell types but is sparsely reported and not fully understood in untransformed cells. We characterize centriole behavior after DNA damage in synchronized untransformed human cells. One hour treatment of S phase cells with the radiomimetic drug, Doxorubicin, prolongs G2 by at least 72 h, though 14% of the cells eventually go through mitosis in that time. By 72 h after DNA damage we observe a 52% incidence of centriole disengagement plus a 10% incidence of extra centrioles. We find that either APC/C or Plk activities can disengage centrioles after DNA damage, though they normally work in concert. All disengaged centrioles are associated with γ-tubulin and maturation markers and thus, should in principle be capable of reduplicating and organizing spindle poles. The low incidence of reduplication of disengaged centrioles during G2 is due to the p53-dependent expression of p21 and the consequent loss of Cdk2 activity. We find that 26% of the cells going through mitosis after DNA damage contain disengaged or extra centrioles. This could produce genomic instability through transient or persistent spindle multipolarity. Thus, for cancer patients the use of DNA damaging therapies raises the chances of genomic instability and evolution of transformed characteristics in proliferating normal cell populations.
© 2014 Wiley Periodicals, Inc.
Publication types
-
Research Support, N.I.H., Extramural
MeSH terms
-
Anaphase-Promoting Complex-Cyclosome / antagonists & inhibitors
-
Anaphase-Promoting Complex-Cyclosome / metabolism
-
Antibiotics, Antineoplastic / toxicity*
-
Cell Cycle Proteins / antagonists & inhibitors
-
Cell Cycle Proteins / metabolism
-
Cell Line
-
Cell Proliferation / drug effects*
-
Cell Transformation, Neoplastic / chemically induced*
-
Cell Transformation, Neoplastic / genetics
-
Cell Transformation, Neoplastic / metabolism
-
Cell Transformation, Neoplastic / pathology
-
Centrioles / drug effects*
-
Centrioles / metabolism
-
Centrioles / pathology
-
Cyclin-Dependent Kinase 2 / antagonists & inhibitors
-
Cyclin-Dependent Kinase 2 / metabolism
-
Cyclin-Dependent Kinase Inhibitor p21 / metabolism
-
DNA Damage*
-
Doxorubicin / toxicity*
-
G2 Phase Cell Cycle Checkpoints / drug effects
-
Genomic Instability
-
Humans
-
Polo-Like Kinase 1
-
Protein Kinase Inhibitors / pharmacology
-
Protein Serine-Threonine Kinases / antagonists & inhibitors
-
Protein Serine-Threonine Kinases / metabolism
-
Proto-Oncogene Proteins / antagonists & inhibitors
-
Proto-Oncogene Proteins / metabolism
-
RNA Interference
-
Retinal Pigment Epithelium / drug effects*
-
Retinal Pigment Epithelium / metabolism
-
Retinal Pigment Epithelium / pathology
-
Time Factors
-
Transfection
-
Tubulin / metabolism
-
Tumor Suppressor Protein p53 / genetics
-
Tumor Suppressor Protein p53 / metabolism
Substances
-
Antibiotics, Antineoplastic
-
CDKN1A protein, human
-
Cell Cycle Proteins
-
Cyclin-Dependent Kinase Inhibitor p21
-
Protein Kinase Inhibitors
-
Proto-Oncogene Proteins
-
TP53 protein, human
-
Tubulin
-
Tumor Suppressor Protein p53
-
Doxorubicin
-
Anaphase-Promoting Complex-Cyclosome
-
Protein Serine-Threonine Kinases
-
CDK2 protein, human
-
Cyclin-Dependent Kinase 2